Our patents


Cantargia's strategy is to obtain an extensive patent protection for its current and future product candidates. Cantargia has patent protection for the treatment of a large number of different cancer forms using antibodies directed against IL1RAP. Cantargia also has a patent family covering the product candidate CAN04, as well as a patent family covering other antibodies targeting IL1RAP. Cantargia's patent strategy is global, and covers markets deemed to be of clinical and commercial relevance for the product pipeline.

Karta
Patent family Patent application Approved patents Validity
Leukemias Europe (France, Germany, UK), USA 2029
Hematological cancers Australia, Canada, China, Europe, Israel, Japan, Mexico, South Africa, USA Australia, Canada, China, Europe (France, Germany, Great Britain, Italy, Netherlands, Spain, Switzerland), Israel, Japan, Mexico, South Africa, USA 2030
Solid tumors Australia, Brazil, Canada, China, Europe, Japan, Mexico, Russia, South Korea, USA Australia, China, Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Great Britain, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland), Japan, Mexico, Russia, USA, 2032
CAN04 Australia, Brazil, Canada, China, Europe, India, Israel, Japan, Mexico, Russia, Singapore, South Africa, South Korea, USA China, Europe (Austria, Belgium, Czech Republic, Denmark, Estonia, France, Germany, Great Britain, Ireland, Italy, Latvia, Lithuania, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Turkey), Japan, Mexico, South Africa, USA, Russia, Singapore, Israel 2035
CAN03 Australia, Brazil, Canada, China, Europe, India, Japan, Mexico, South Korea, USA USA 2035
Anti-IL1-RAP antibodies Australia, Canada, China, Europe, India, Japan, USA 2037